Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03025035 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
A Phase 2 study, sponsored by Yuan Yuan.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT03025035 is a Phase 2 study that has completed, run by Yuan Yuan. The registered enrollment target is 14 participants.
The verdict
NCT03025035, a Phase 2 study, has completed, sponsored by Yuan Yuan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This trial will evaluate the use of immunotherapy and PARP inhibition in a population with incurable advanced breast cancer associated with a germline BRCA mutation or HDR-defect. The main objective is to examine overall response rate of pembrolizumab (immunotherapy) in combination with Olaparib (PARP inhibitor) in advanced BRCA-mutated or Homology-directed repair (HDR)-defect breast cancer.
Interventions
- DRUG Pembrolizumab
- DRUG Olaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-09-10 |
| Est. Completion | 2025-11-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03025035
The ClinicalTrials.gov registry entry for NCT03025035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yuan Yuan, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03025035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03025035 about?
NCT03025035 is a clinical study titled "Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer". This trial will evaluate the use of immunotherapy and PARP inhibition in a population with incurable advanced breast cancer associated with a germline BRCA mutation or HDR-defect. The main objective is to examine overall response rate of pembrolizumab (immunotherapy) in combination with Olaparib (PA...
What is the current status of trial NCT03025035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2017-09-10. Estimated completion is 2025-11-21.
What interventions are being tested in trial NCT03025035?
The interventions under investigation include: Pembrolizumab (DRUG), Olaparib (DRUG).
Who is sponsoring clinical trial NCT03025035?
This trial is sponsored by Yuan Yuan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.